WASHINGTON -- Hidden within the mammoth omnibus appropriations bill crafted by House, Senate and White House negotiators is a 19-word change to a ride...

WASHINGTON -- A group of 60 House Democrats led by Rep. Anna Eshoo (D-Calif.) is urging the White House to sign a draft executive order that would req...

WASHINGTON -- Congressional Democrats are stepping up support for transparency in corporate political spending ahead of the 2012 elections. On Wedn...

Democrats in Congress have just proudly signed a deal that allows a bunch of old men who have spent the better part of the last century avoiding their own sexual issues to dictate access to abortion services.

The public option has received the lion's share of attention in the health care debate, but there's an equally important issue relating to generic drugs that could mean lifesaving drugs remain too expensive for all but the wealthy.

WASHINGTON — Television viewers jarred by abrupt spikes in volume during commercial breaks may someday be able to give their mute buttons a rest...

Jane Hamsher attributes nefarious motives to our health care reform effort and the resulting legislation. I fiercely disagree. It was carefully shaped to save lives and reduce costs.

Thank you, Rep. Eshoo, for your commitment to having a bill that does not allow for "evergreening." Now the question becomes -- how are we going to get one?

You know a health care bill isn't right for the American people when it carves out a legal monopoly for Big Pharma and Botox. Our Congressional leaders should be capable of more.

Pelosi made a choice about the lifesaving biologic drugs I took when I was in chemotherapy that will cost many fellow breast cancer survivors everything they own, and quite possibly their lives.

In Congress, I will work to support affordable prices on biologics, so that victims of cancer, HIV, diabetes, Parkinsons, rheumatoid arthritis, and multiple sclerosis can afford the medicine they need to stay alive.

The Eshoo/Barton amendment, which has the support of many newly pro-PhRMA democrats, will extend the period of monopolies for biologic medicines.

Unlike for pharmaceutical drugs, there is no easy way to get FDA approval for a generic biologic product. Congress is considering an FDA reform to fix this, but it is being derailed by the BIO.

The revelation from seven Democrats on the House Intelligence Committee that they were misled about a critical CIA program has sparked a debate that t...